The activation process allows the cells, antibodies, and organs of the immune system work to protect and defend the body against tumor cells. Upon encountering a tumor cell, the activated NK cell attaches to the membrane of the cancer cell and injects toxic granules that quickly dissolve the target cell. In less than five minutes, the cancer cell would be dead and the NK cell moves on to its next target. A single NK cell can destroy up to 27 cancer cells before it dies. Clinical protocol has shown that the immune system may also be capable of determining the difference between cancer and healthy cells, thus lowering the possibility of side effects during the treatment process. It is through such cutting-edge technology that Nichi-Asia was awarded Bionexus status by BiotechCorp last year.
The company is not only focusing on providing commercial services for the public, but is also strongly dedicated to developing its own research, while enhancing the biotechnology human capital for the country through its establishment of its research labs in Malaysia. The research labs have been designed with expert input from distinguished Japanese scientists Dr. Terunuma Hiroshi and Dr. Sam JK Abraham of the Biotherapy Institute of Japan and Yamanashi Medical University respectively and looks set to be one of the foremost stemcell research laboratories in the country.
We are currently following very closely in the developmental footsteps of NCRM through our collaboration with them,!¨ comments Dr. Krishnamoorty. The institution which started in September 2005 to date has managed to become the pioneers of immunotherapy for cancer treatment as well as stem cell treatment for diabetic ischmetic foot and spinal cord injury in India. Up to 300 patients have been treated through their stem cell therapy, with 2 publications and 10 clinical presentations at international meetings to date. They also count on seven collaborations with research institutes in India with two patents on stem cell applications among their jewels.
Dr. Krishnamoorty has great hopes for Nichi-Asia as he believes its unique edge allows it to have a great foothold in the country!|s industry. I believe that the development of the biotech industry relies on many factors, and I believe that we havesuch an edge as we are not only expanding in terms of commercial services but also doing cutting edge research and building up on human capital for the country.
On a larger scale, we hope that Nichi-Asia would also help Malaysia gain more ground in terms of developing medical tourism in Malaysia as we are currently the only such company in the region with this unique form of technology. We hope to be able to garner greater prominence and respect from the medical community on a local and international through our efforts.